We are live on ! Find out more
RARX

Ra Pharmaceuticals, Inc. Common Stock
RARX

Delisted

RARX was delisted on the 1st of April, 2020.

Back to rankings

66 hedge funds and large institutions have $131M invested in Ra Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

11% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 18

3% more funds holding

Funds holding: 64 → 66 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

43% less capital invested

Capital invested by funds: $230M → $131M (-$98.7M)

Holders
66
Holders Change
+2
Holders Change %
+3.13%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
20
Reduced
18
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$5.83M
2
BlackRock
BlackRock
New York
+$3.79M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.23M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$574K
5
PP
PDT Partners
New York
+$569K

Top Sellers

Rank Fund Capital Flow
1
SAM
Sectoral Asset Management
Quebec, Canada
-$4.06M
2
GTC
Ghost Tree Capital
New York
-$3.43M
3
VMI
VHCP Management II
New York
-$2.77M
4
Millennium Management
Millennium Management
New York
-$2.3M
5
Ameriprise
Ameriprise
Minnesota
-$1.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$29.7M – – –
Wellington Management Group
2
Wellington Management Group
Massachusetts
$23.5M +$5.83M +474,202 +21%
NHAS
3
Novo Holdings A/S
Denmark
$17.3M – – –
RCM
4
RA Capital Management
Massachusetts
$11.5M – – –
BlackRock
5
BlackRock
New York
$8.1M +$3.79M +308,452 +48%
RSCM
6
Rock Springs Capital Management
Maryland
$5.1M – – –
VMI
7
VHCP Management II
New York
$4.63M -$2.77M -225,159 -29%
Millennium Management
8
Millennium Management
New York
$3.78M -$2.3M -187,060 -30%
Vanguard Group
9
Vanguard Group
Pennsylvania
$3.33M +$435K +35,375 +10%
TCM
10
Tekla Capital Management
Massachusetts
$3.03M -$487K -39,581 -10%
Citadel Advisors
11
Citadel Advisors
Florida
$2.54M -$245K -19,947 -6%
JP Morgan Chase
12
JP Morgan Chase
New York
$2.32M +$210K +17,077 +7%
BBA
13
Baker Bros. Advisors
New York
$1.51M – – –
State Street
14
State Street
Massachusetts
$1.35M +$40K +3,251 +2%
CS
15
Candriam SCA
Luxembourg
$1.28M +$430K +35,000 +30%
Northern Trust
16
Northern Trust
Illinois
$1.17M +$14.8K +1,207 +0.9%
PC
17
Polar Capital
United Kingdom
$1.06M -$615K -50,000 -29%
RPAM
18
Rhenman & Partners Asset Management
Sweden
$922K -$138K -11,246 -9%
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$850K +$1.23M +100,000 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$715K +$91.4K +7,435 +10%
DM
21
Deerfield Management
New York
$673K -$283K -23,000 -23%
OAM
22
Oxford Asset Management
United Kingdom
$493K -$128K -10,421 -15%
Jacobs Levy Equity Management
23
Jacobs Levy Equity Management
New Jersey
$397K +$574K +46,660 New
PP
24
PDT Partners
New York
$394K +$569K +46,300 New
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$371K +$537K +43,703 New
1
2 3 4

RARX Hedge Fund Activity: Q4 2017 in Review

66 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q4 2017, worth a combined $131M — down 43% from $230M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RARX positions and 15 closed out — a net gain of 2 holders — while 20 added to existing stakes and 18 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $5.83M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $4.06M sold.

  • 66 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q4 2017, up from 64 in Q3 2017.
  • Funds reported $131M of Ra Pharmaceuticals, Inc. Common Stock stock for Q4 2017, down 43% quarter-over-quarter.
  • 17 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 15 closed out, a net change of +2 holders.
  • The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was Wellington Management Group, an estimated $5.83M added.
  • The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was Sectoral Asset Management, an estimated $4.06M sold.

Based on aggregated 13F filings for Q4 2017.